Fulcrum Therapeutics, Inc. (FULC) Stock

About Fulcrum Therapeutics, Inc.

Fulcrum Therapeutics, Inc. is led by CEO Alexander C. Sapir, employs 45 people, headquartered in US, publicly traded since 2019.

Fulcrum Therapeutics, Inc. (FULC) stock trades at $3.68 with a market capitalization of $280.77M. The stock is valued at a negative price-to-earnings (P/E) ratio of -3.05, reflecting a net loss over the last twelve months, price-to-book of 0.91, price-to-sales of 0.00. Over the past 52 weeks the stock has ranged between $2.83 and $15.74, and currently trades 76.6% below its 52-week high.

On profitability, Fulcrum Therapeutics, Inc. generates a return on equity (ROE) of -28.54% (negative, reflecting a net loss), return on capital employed of -27.62%.

Fulcrum Therapeutics, Inc. by the numbers, 2017–2025

Between 2017 and 2025 Fulcrum Therapeutics, Inc. reported revenue of $0 rising to $0. Compounded, revenue has grown —% a year over five years, —% over three, —% over the last twelve months. Net profit fell to $-75.0M.

On a trailing twelve-month basis to Jun '26, revenue is $0 and net profit $-85.0M.

Borrowings fell from $35.0M to $6.0M, cash from operations was $-60.0M in the latest year, positive in 0 of the last 9.

Return on equity has averaged -32.1% over five years, and was -21.5% in the most recent year.

The share price itself has compounded at —% a year over five years, —% over three, —% over the last year. Past price movement is history, not a forecast.

Figures are as reported and in the company's own reporting currency. They describe what has already happened and carry no implication about what follows.

Fulcrum Therapeutics, Inc. (FULC) — frequently asked questions